PMID: 3762187Oct 1, 1986Paper

Implantable venous access devices: an alternative method of extended cancer care

Journal of Surgical Oncology
R E WellingJ J Arbaugh

Abstract

The advent of totally implantable venous access devices (TIVADs) is changing the method of treatment for those chronically ill patients who require long-term chemotherapy or narcotic infusion. TIVADs eliminate the problem of limited peripheral vein access with little risk of complication. At Good Samaritan Hospital in Cincinnati, Ohio, we have implanted 30 TIVADs (3 Infuse-A-Ports and 27 Port-a-Caths) for a total of 4,502 patient days. This report documents our experience with the implantation and utilization of TIVAD systems.

References

Dec 1, 1983·Annals of Internal Medicine·F D Lowy, S M Hammer
Oct 1, 1984·The American Journal of Medicine·S Ponce de Leon, R P Wenzel
Apr 1, 1984·American Journal of Surgery·A BotheJ J Lokich
Dec 1, 1982·The American Journal of Medicine·J GyvesR Wheeler

❮ Previous
Next ❯

Citations

May 1, 1990·Journal of Surgical Oncology·K J Grannan, P H Taylor
Sep 17, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·L LaurenziE Arcuri
Nov 1, 1987·The Australian and New Zealand Journal of Surgery·H L Carmalt, D Duggan
Dec 1, 1988·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·B GruberW R Panje
Nov 1, 1988·Journal of Surgical Oncology·D M AlpeterJ Arbaugh

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.